NCT00492284View on ClinicalTrials.gov

Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)

PHASE2CompletedINTERVENTIONAL

Enrollment

162

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2010

Conditions

Choroidal NeovascularizationMacular Degeneration

Interventions

DRUG

verteporfin

Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)

DRUG

verteporfin

Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)

DRUG

ranibizumab

0.5 mg intravitreal injection

DRUG

dexamethasone

0.5 mg intravitreal injection

Trial Locations (26)

Unknown

Mobile

Phoenix

Retina Centers, PC, Tucson

Beverly Hills

Campbell

Los Angeles

Poway

Sacramento

Torrance

Fort Myers

Indianapolis

Davenport

Missoula

Omaha

Portsmouth

Portland

Philadelphia

West Mifflin

Arlington

Temple

Seattle

Calgary

Vancouver

Halifax

London

Toronto

All Listed Sponsors

lead

QLT Inc.

INDUSTRY

NCT00492284 - Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) | Biotech Hunter | Biotech Hunter